X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DIVIS LABORATORIES - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DIVIS LABORATORIES FRESENIUS KABI ONCO./
DIVIS LABORATORIES
 
P/E (TTM) x 22.1 29.1 76.1% View Chart
P/BV x 3.1 5.0 61.8% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 FRESENIUS KABI ONCO.   DIVIS LABORATORIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DIVIS LABORATORIES
Mar-17
FRESENIUS KABI ONCO./
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1761,222 14.4%   
Low Rs79784 10.0%   
Sales per share (Unadj.) Rs37.7153.1 24.6%  
Earnings per share (Unadj.) Rs5.139.9 12.8%  
Cash flow per share (Unadj.) Rs6.744.6 15.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs42.5201.8 21.1%  
Shares outstanding (eoy) m158.23265.47 59.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.46.6 51.5%   
Avg P/E ratio x25.025.1 99.5%  
P/CF ratio (eoy) x18.922.5 84.1%  
Price / Book Value ratio x3.05.0 60.2%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m20,135266,266 7.6%   
No. of employees `0001.29.7 11.8%   
Total wages/salary Rs m7034,687 15.0%   
Avg. sales/employee Rs Th5,176.24,175.0 124.0%   
Avg. wages/employee Rs Th610.4481.5 126.8%   
Avg. net profit/employee Rs Th699.61,089.3 64.2%   
INCOME DATA
Net Sales Rs m5,96340,643 14.7%  
Other income Rs m18749 2.4%   
Total revenues Rs m5,98141,392 14.4%   
Gross profit Rs m1,43014,460 9.9%  
Depreciation Rs m2581,233 20.9%   
Interest Rs m-2623 -115.0%   
Profit before tax Rs m1,21613,953 8.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3423,349 10.2%   
Profit after tax Rs m80610,604 7.6%  
Gross profit margin %24.035.6 67.4%  
Effective tax rate %28.124.0 117.2%   
Net profit margin %13.526.1 51.8%  
BALANCE SHEET DATA
Current assets Rs m5,10240,105 12.7%   
Current liabilities Rs m2,3856,595 36.2%   
Net working cap to sales %45.682.5 55.2%  
Current ratio x2.16.1 35.2%  
Inventory Days Days150119 126.6%  
Debtors Days Days11381 140.4%  
Net fixed assets Rs m5,14819,995 25.7%   
Share capital Rs m158531 29.8%   
"Free" reserves Rs m6,55653,043 12.4%   
Net worth Rs m6,73253,574 12.6%   
Long term debt Rs m9520-   
Total assets Rs m10,38861,585 16.9%  
Interest coverage x-45.8618.4 -7.4%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.7 87.0%   
Return on assets %7.517.3 43.5%  
Return on equity %12.019.8 60.5%  
Return on capital %14.626.1 56.0%  
Exports to sales %74.50-   
Imports to sales %24.825.2 98.2%   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,47710,259 14.4%   
Fx inflow Rs m5,29835,384 15.0%   
Fx outflow Rs m1,77210,399 17.0%   
Net fx Rs m3,52524,985 14.1%   
CASH FLOW
From Operations Rs m1,27411,493 11.1%  
From Investments Rs m-1,204-11,372 10.6%  
From Financial Activity Rs m-196-93 210.6%  
Net Cashflow Rs m-12628 -444.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 9.6 19.0 50.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   42,599 31,796 134.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS